Centessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Large Increase in Short Interest

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 1,450,000 shares, an increase of 27.2% from the June 30th total of 1,140,000 shares. Currently, 2.1% of the shares of the stock are sold short. Based on an average trading volume of 246,600 shares, the days-to-cover ratio is currently 5.9 days.

Centessa Pharmaceuticals Trading Up 4.8 %

Shares of NASDAQ CNTA opened at $10.78 on Friday. Centessa Pharmaceuticals has a 1 year low of $5.15 and a 1 year high of $12.45. The firm’s 50-day moving average is $9.10 and its 200-day moving average is $9.57. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Monday, May 13th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.03. Equities analysts expect that Centessa Pharmaceuticals will post -1.62 EPS for the current year.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of analyst reports. BMO Capital Markets restated an “outperform” rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Morgan Stanley increased their target price on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Friday, June 21st. Finally, Oppenheimer assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, July 18th. They issued an “outperform” rating and a $14.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Large investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in Centessa Pharmaceuticals by 69.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after acquiring an additional 4,423 shares during the period. Quarry LP acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $48,000. EntryPoint Capital LLC acquired a new stake in Centessa Pharmaceuticals during the 1st quarter worth approximately $109,000. Jump Financial LLC bought a new position in Centessa Pharmaceuticals in the fourth quarter valued at approximately $114,000. Finally, Trexquant Investment LP acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $114,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.